Aggressive T-cell lymphoma
Conditions
Interventions
one:thalidomide plus CHOP-like regimen
two:CHOP-like chemotherapy
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients must meet the following criteria for study entry: 1. Any Sex; Unpregnancy; 2. Aged 18 to 75 years old; 3. All patents are diagnosed by pathology; 4. ECOG performance status of 0-1; 5. No abnormality of liver and kidney function; 6. No serious complications of severe systemic infection, severe anemia and cachexia; 7. On their own or someone else to fill in the complete scale; 8. Agreed to participate in this study.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will be excluded from study entry: 1. Childbearing age and recent family planning women; 2. involved other cancer therapy clinical trials; 3. Thalidomide or within any chemotherapy drug allergy; 4. Patients with mechanical gastrointestinal obstruction; 5. With other serious systemic diseases; 6. There is a history of thromboembolism, except caused by PICC.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival;Total efficiency;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| complete response;partial response; | — |
Countries
China
Contacts
Public ContactGang Wu
Union Hospital,Tongji Medical College,Huazhong University of Science and Technology
Outcome results
None listed